Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia

Schizophrenia Research
Stephen Z LevineStefan Leucht

Abstract

Dropout is a serious challenge to clinical trials in psychiatry, yet standard outcome analyses with mixed models do not account for dropout, while joint modeling uses dropout from a survival model to adjust the outcome from a mixed model, but is untested in clinical trials of schizophrenia. To compare mixed and joint modeling in three acute phase pivotal placebo controlled trials of schizophrenia. Data were reanalyzed on 611 in-patients with acute schizophrenia who participated in three pivotal randomized controlled trials that compared placebo with olanzapine or risperidone (dropout rates placebo: 62.6% and medication: 37.4%). The outcome measures were BPRS or PANSS total change scores. Mixed-effects models for repeated measures and joint models were computed and compared to examine the time-treatment interaction. Effect size comparisons were made. Antipsychotic treatment was superior to placebo across analyses. Time treatment interactions were significant (p<.05) for the mixed (beta=2.33) and joint models (beta=2.62). Compared with mixed modeling, joint modeling reduced the estimated change score for treatment (21.24 vs 19.74) and placebo (1.64 vs -1.11). The effect size differences between placebo and treatment groups were g...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Mar 1, 1996·Psychopharmacology·C M BeasleyS Hamilton
Jan 15, 1997·Statistics in Medicine·J W Hogan, N M Laird
Jul 4, 2001·Psychopharmacology·K WahlbeckS Leucht
Apr 23, 2003·Biological Psychiatry·Craig H MallinckrodtGary D Tollefson
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 7, 2005·Archives of General Psychiatry·Georg KemmlerW Wolfgang Fleischhacker
Dec 29, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·José Luis R MartinEnric Alvarez
Mar 18, 2006·Biometrics·Li C Liu, Donald Hedeker
Mar 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Terry Therneau
Feb 26, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S LeuchtR R Engel
Mar 5, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Wan SunYaning Wang
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Apr 5, 2014·Journal of Biopharmaceutical Statistics·T BaghfalakiR Hashemi
Oct 15, 2014·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Divine E EdiebahMartin J B Taphoorn

❮ Previous
Next ❯

Citations

Jun 19, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtJohn M Davis
Dec 7, 2016·BMC Medical Research Methodology·Maria SudellCatrin Tudur-Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here